Acebilustat (also known as CTX-4430) is a new once-daily oral anti-inflammatory drug in development for treatment of cystic fibrosis (CF) and other diseases. It is an inhibitor of leukotriene A4 hydrolase, which is responsible for the production of leukotriene B4 (LTB4). The later is a molecule that leads to inflammation. Therefore, Acebilustat can treat inflammation through suppressing the production of leukotriene B4.
https://www.cff.org/Trials/Pipeline/details/108/CTX-4430
Springman, E., et al. "127 Pharmacokinetic and pharmacodynamic profile of CTX-4430 in two phase 1 studies." Journal of Cystic Fibrosis14(2015):S90-S90.
Springman, E., et al. "126 A phase 1 clinical study of CTX-4430 in cystic fibrosis patients." Journal of Cystic Fibrosis 14(2015):S90-S90.
Elborn, J. S., et al. "Phase I Studies of Acebilustat: Pharmacokinetics, Pharmacodynamics, Food Effect, and CYP3A Induction." Clinical & Translational Science 10.1(2017):20-27.
